Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: To Cliff, Carl, Gloria
" Think about such an event, and how much more successful your investment would be without TPL's continued public association with the MMP licensing program, and damaging influence on our shareholder communications, transparency, and stock price." . . . . . . . . Any plan MUST have an exit strategy whereby Chuck Moore is able to join up with PTSC and be held harmless. That means driving TPL hard enough into the ground that Chuck can have a legal reason to annul his agreement with TPL. If that can be done, the "new" PDS can have Chuck and TPL as 50/50 partners and Agilent as the litigators. How clean does THAT sound?
Share
New Message
Please login to post a reply